Kavar Capital Partners Group’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History
Bought
Maintained
Sold
Other funds holding BSX.PRA
ACM
WHG
Kavar Capital Partners Group's BSX.PRA Position: Q3 2022 in Review
Kavar Capital Partners Group sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q3 2022, closing a stake of 6,200 shares — an estimated $629K sold.
Kavar Capital Partners Group first reported a position in BSX.PRA in Q3 2020 and held it in 2 quarters. The position peaked at $629K in Q2 2022. 54 funds tracked by Wall St. Rank hold BSX.PRA as of Q3 2022.
- Kavar Capital Partners Group reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q3 2022 after selling out during the quarter.
- Kavar Capital Partners Group sold 6,200 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q3 2022, an estimated $629K.
- Kavar Capital Partners Group first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q3 2020 and held it in 2 quarters.
- Kavar Capital Partners Group's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $629K in Q2 2022.
- 54 funds tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q3 2022.
Based on Kavar Capital Partners Group's 13F filing for Q3 2022, filed 8 Nov 2022.